Related Experiment Video

Updated: Aug 30, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

ACE inhibitors and beta blockers in chronic congestive cardiac failure: therapeutic basis

P C Manoria1, Pankaj Manoria

  • 1Department of Cardiology, Gandhi Medical College, Bhopal.

Journal of the Indian Medical Association
|October 25, 2003
PubMed

Insights

Congestive cardiac failure (CCF) is a global health issue. Angiotensin-converting enzyme inhibitors (ACEI) and beta blockers (BB) significantly reduce CCF morbidity and mortality, yet remain underutilized.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive cardiac failure (CCF) presents a significant global health challenge, marked by high morbidity and mortality rates.
  • Neurohormonal activation accelerates CCF progression, increasing patient risk.

Purpose of the Study:

  • To highlight the efficacy of Angiotensin-Converting Enzyme Inhibitors (ACEI) and Beta Blockers (BB) in managing CCF.
  • To emphasize the underutilization of ACEI and BB in CCF treatment and advocate for increased medical awareness and adoption.

Main Methods:

  • Review of existing literature on ACEI and BB in cardiovascular conditions.
  • Analysis of the impact of ACEI and BB on morbidity and mortality in CCF patients.

Main Results:

  • ACEI and BB effectively blunt disease progression in CCF by inhibiting neurohormonal activation.
  • These medications demonstrate a major positive impact on reducing morbidity and mortality associated with CCF.
  • ACEI and BB are also beneficial for asymptomatic left ventricular dysfunction (LVD) and preventing heart failure in high-risk individuals.

Conclusions:

  • ACEI and BB are crucial, underutilized therapies for CCF.
  • There is an urgent need to educate healthcare professionals on the enhanced use of ACEI and BB for improved patient outcomes.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.